FDA grants EUA for Visby Medical's COVID-19 test

By LabPulse.com staff writers

September 13, 2021 -- The U.S. Food and Drug Administration (FDA) has granted an emergency use authorization (EUA) for Visby Medical's COVID-19 reverse transcription polymerase chain reaction test for pooled samples.

The authorization expands the company's first EUA for single-patient-sample testing to pooled testing of up to five samples at once for SARS-CoV-2, Visby said.

FDA clears Visby Medical's sexual health test
The U.S. Food and Drug Administration (FDA) has cleared Visby Medical's Sexual Health Click test, a polymerase chain reaction test for identifying Chlamydia...
Visby gets $12M to make flu/COVID-19 self-tests
Visby Medical has received $12.3 million in U.S. government funding to speed up the development of its rapid, single-use flu/COVID-19 polymerase...
Firm developing rapid gonorrhea test wins $19M prize
A company developing a rapid diagnostic test for the microorganism that causes gonorrhea has won $19 million in a challenge that's part of the U.S....

Copyright © 2021 LabPulse.com

Last Updated ls 9/13/2021 4:35:39 PM



Subscribe Today
Do you want to be a Microbiology Insider?

When LabPulse gets hot new information, our Insiders are the first to find out. Stay current in today's competitive market by receiving our exclusive free email updates.

Yes, Keep Me Current